Benefit‐Risk Assessment of Off‐Label Drug Use in Children: The Bravo Framework-Reference-Cited by-同舟云学术

Benefit‐Risk Assessment of Off‐Label Drug Use in Children: The Bravo Framework

Published:2021-07-29 Issue:4 Volume:110 Page:952-965
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Zanden Tjitske M.¹²³,Mooij Miriam G.⁴,Vet Nienke J.⁵,Neubert Antje⁶,Rascher Wolfgang⁶,Lagler Florian B.⁷,Male Christoph⁸,Grytli Helene⁹,Halvorsen Thomas¹⁰,Hoog Matthijs¹,Wildt Saskia N.²³¹¹

Affiliation:

1. Department of Pediatrics Erasmus MC – Sophia Children’s Hospital Rotterdam The Netherlands

2. Departments of Pharmacology and Toxicology, and Intensive Care Radboud Institute Health Sciences Radboud University Medical Center Nijmegen The Netherlands

3. Dutch Knowledge Center Pharmacotherapy for Children Den Haag The Netherlands

4. Department of Pediatrics Leiden University Medical Centre – Willem‐Alexander Children’s Hospital Leiden The Netherlands

5. Department of Pediatrics St. Antonius Hospital Nieuwegein The Netherlands

6. Department of Pediatric and Adolescent Medicine University Hospital Erlangen Erlangen Germany

7. Department for Pediatrics and Institute for Inherited Metabolic Diseases Paracelsus Medical University Salzburg Austria

8. Department of Paediatrics and Adolescent Medicine Medical University of Vienna Austria

9. The Norwegian Medicines Manual for Health Personnel and Institute for Cancer Research Oslo University Hospital Oslo Norway

10. Department of Pediatric and Adolescent Medicine Medicines for Children Network, Norway Haukeland University Hospital Bergen Norway

11. Intensive Care and Pediatric Surgery Erasmus MC Sophia Children’s Hospital Rotterdam The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2336

Reference86 articles.

1. Weda M.et al.Study on the off‐label use of medicinal products in the European Union.www.ec.europa.com; 2017 [updated March 14 2017].

2. Two decades of off-label prescribing in children: a literature review

3. Off‐label medication use in children, more common than we think: a systematic review of the literature;Allen H.C.;J. Okla. State Med. Assoc.,2018

4. Ten Common Questions (and Their Answers) About Off-label Drug Use

5. BAP Position Statement: Off-label prescribing of psychotropic medication to children and adolescents

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing empagliflozin in individuals with glycogen storage disease Ib: A value‐based healthcare approach and systematic benefit‐risk assessment;Journal of Inherited Metabolic Disease;2024-01-07

2. Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses;Expert Review of Clinical Pharmacology;2023-11-29

3. Off-Label Prescribing in Pediatric Population—Literature Review for 2012–2022;Pharmaceutics;2023-11-21

4. A Callout for International Collaboration. Reply to Giger, E.V.; Tilen, R. Comment on “Shaniv et al. Neonatal Drug Formularies—A Global Scope. Children 2023, 10, 848”;Children;2023-11-13

5. Comparative Analysis of Oral Ondansetron, Metoclopramide, and Domperidone for Managing Vomiting in Children With Acute Gastroenteritis;Cureus;2023-10-24